| Literature DB >> 36076806 |
Antonio Cascajosa-Lira1, Pedro Andreo-Martínez2, Ana Isabel Prieto1, Alberto Baños3, Enrique Guillamón3, Angeles Jos1, Ana M Cameán1.
Abstract
Organosulfur compounds (OSCs) are secondary metabolites produced by different Allium species which present important biological activities such as antimicrobial, antioxidant, anti-inflammatory antidiabetic, anticarcinogenic, antispasmodic, etc. In recent years, their use has been promoted in the agri-food industry as a substitute for synthetic preservatives, increasing potential accumulative exposure to consumers. Before their application in the food industry, it is necessary to pass a safety assessment as specified by the European Food Safety Authority (EFSA). This work reviews the scientific literature on OSCs regarding their in vitro toxicity evaluation following PRISMA guidelines for systematic reviews. Four electronic research databases were searched (Web of Science, Scopus, Science Database and PubMed) and a total of 43 works were selected according to predeterminate inclusion and exclusion criteria. Different data items and the risk of bias for each study were included. Currently, there are very few in vitro studies focused on investigating the potential toxicity of OSCs. Most research studies aimed to evaluate the cytotoxicity of OSCs to elucidate their antiproliferative effects focusing on their therapeutic aspects using cancer cell lines as the main experimental model. The results showed that diallyl disulfide (DADS) is the compound most studied, followed by diallyl trisulfide (DATS), diallyl sulfide (DAS), Allicin and Ajoene. Only 4 studies have been performed specifically to explore the safety of OSCs for agri-food applications, and genotoxicity studies are limited. More toxicity studies of OSCs are necessary to ensure consumers safety and should mainly be focused on the evaluation of genotoxicity and long-term toxicity effects.Entities:
Keywords: Allium; bioactive organosulfur compounds; in vitro; natural additive; toxicity
Year: 2022 PMID: 36076806 PMCID: PMC9455835 DOI: 10.3390/foods11172620
Source DB: PubMed Journal: Foods ISSN: 2304-8158
Organosulfur compounds present in Allium species, chemical structure and main properties.
| Name | Chemical Structure | Mode of Action | Reference |
|---|---|---|---|
| E-Ajoene |
| Antibacterial: in vitro activity against Gram +: | [ |
| Antifungal: MIC = 15–50 µg/mL | |||
| Antioxidant enzyme induction: NAD(P)H: quinone oxidoreductase-1 (NQO1) | [ | ||
| Alliin |
| Antioxidant: superoxide scavenging activity | [ |
| Allicin |
| Antibacterial: in vitro activity against | [ |
| Antifungal: MIC = 1.52–6.25 µg/mL | [ | ||
| Antioxidant activity in vivo: SOD and GSH-Px activities | [ | ||
| Di-allyl-disulphide |
| Antibacterial activity against | [ |
| Antifungal activity against | [ | ||
| Antioxidant in vivo activity | [ | ||
| Di-allyl-sulphide |
| Antibacterial activity against | [ |
| Antifungal activity against | [ | ||
| Antioxidant in vivo activity | [ | ||
| Di-allyl-trisulphide |
| Antibacterial activity against | [ |
| Antifungal activity against | [ | ||
| Antioxidant in vitro activity | [ | ||
| Dipropyl disulphide |
| Antioxidant in vitro activity | [ |
| Dipropyl sulphide |
| Antioxidant in vitro activity | [ |
| Propyl-propane-tiosulphonate |
| Antibacterial activity against Gram +: MCB = 0.5–10 µg/mL and Gram-: MCB = 1.25–10 µg/mL | [ |
| Antifungal: | [ | ||
| Antiprotozoal and Antiparasitic: reduce the number of apicomplexa in monogastric animals. | [ | ||
| Antioxidant | [ | ||
| Propyl-propane-tiosulphinate |
| Antibacterial activity against Gram -: MCB = 128–1024 µg/mL and Gram +: MCB = 128 µg/mL | [ |
| Antifungal activity | [ | ||
| Antiprotozoal and antiparasitic: reduce the number of Apicomplexa in monogastric animals. | [ | ||
| S-allylcysteine |
| Antioxidant activity by scavenging ROS | [ |
| Vinyldithiin |
| Antioxidant activity | [ |
Figure 1PRISMA flowchart of article selection.
Overview of the studies reporting the in vitro toxicological evaluation of OSCs from Allium spp.
| Assays Performed | Experimental Model | Concentration Ranges and Time Exposure | Main Results | Reference | |
|---|---|---|---|---|---|
| Ajoene | Survival by MTT assay | FS4 | 5–20 µg/mL for 48 h. | EC50(ajoene): FS4 (36 µM) > BHK21 (30 µM) > BJA-B (12 µM). | [ |
| Ajoene | Metabolic activity by MTT assay | BJA-B cells | 173 and 82 nmol/mL for 0–6 h. | In both experiments, ↓ cell viability in a dose and time dependent manner. | [ |
| DDS | Clonal survival | Control and differentiated HT29 cells | 1–3 µg/mL DDS 24 h | Dq (concentration at which no cell killing occurs) 0.10 ± 0.03 µg/mL for DAS and was not found for DDS. | [ |
| DAS, DADS | Clonal survival | CHO | 100–600 µg/mL DAS | Cytotoxicity DADS > DAS. | [ |
| DAS, DADS, DPS, DPDS | Ames test | Ames test: | Ames test was performed with S9 and microsomes from DAS-, DADS-, DPS-, DPDS-treated rats (1 mmol/Kg) | DAS, DPS, DPDS: increased activation of BaP, CP, N-PiP and PhIP, while DADS only increased mutagenicity of PhIP. | [ |
| DAS, DADS, garlic extract | Cytotoxicity by MTT assay | p-53-wild type H460 and p-53-null type H1299 non-small cell lung cancer cells (NSCLC) | DAS and DADS (0–25 µM) and garlic extract (0–200 µg/mL) for 1 h | The cell growth was significantly inhibited by DAS and DADS and slightly inhibited by garlic extract. The OSCs compounds and garlic extract have apoptotic potential on lung cancer cells, and the mechanism was regulated through p53-dependent or p-53 independent related Bax/Bcl-2 dual pathway. | [ |
| DADS | Cell viability and apoptosis by flow cytometry | SH-SY5Y | 50 µM for 12 and 24 h | Blockage in G2/M phase | [ |
| DADS | Survival by MTT assay | N18D3 | 10–200 µM for 2 h. | Cellular viability was not affected up to 25 µM DAS. | [ |
| Allicin | Cell proliferation by MTT assay | AGS | 5–100 µg/mL for 6, 12, 24 and 48 h. | Allicin caused inhibition of cellular growth in a concentration- and time-dependent manner. | [ |
| Ajoene | MTS/PMS chromogenic assay | B16/BL6 | 10–100 µM for 24 h | IC50(B16/BL6) = 18 µM | [ |
| DAS, DADS, DATS | Cell viability by trypan blue exclusion assay | T98G | 100 µM DAS | The three garlic compounds induced cytotoxic effects via ROS production, increase in endoplasmic reticulum (ER) stress, decrease mitochondrial membrane potential, activation of stress kinases and cysteine proteases. | [ |
| Allicin | NIH-3T3 | 0.2–25 µM | Depolymerizing effect of allicin in a concentration-dependent manner until 25 µM. | [ | |
| Ajoene (≥98%) | Cell viability by MTS assay | B16F10 | 1, 5, 10 µmol/L for 24 h | 5 and 10 µmol/L ↓ cell viability and this cytotoxic effect was not prevented by the addition of mevalonate or GGPP. | [ |
| DADS | Cell viability by MTT assay | MCF-7 | 50–400 μmol/L for 24 h. | ↓ cellular viability and ↑ apoptosis in concentration-dependent manner. These effects were observed mainly from 200 μmol/L of treatment. | [ |
| DAS | Cell viability by trypan blue exclusion assay | Colo 320 DM | 5–75 µM for 0–24 h | 50 µM ↓ cell viabilityALP and LDH decreased with time. ROS increased.~55% apoptosis. Cell cycle arrest at G2/M Oligonucleosomal-laddering, characteristic of apoptosis.Higher protein expression of caspase-3 and NF-κB and lower expression of ERK-2. | [ |
| DADS | MTT assayApoptosis by flow cytometry, DNA fragmentation assay and morphology analysisWestern blot analysis of the expression of phosphor-MAPKs (ERK, p38) | HL-60 | 1.25–20 mg/L for 96 h | 10 mg/L ↓59.6% cell viability | [ |
| DATS | MTT assay | A375 | 5–60 µM for 24, 48, 72 h | IC50(A375) = 11.7 µM | [ |
| n-DADS | MTT assay | MCF-7 | 0.01–2.00 mmol/L 48 for 72 h. | s- and n-DADS present concentration- and time-dependent inhibitory effects and similar cytotoxicity in MCF-7 cells. | [ |
| DATS | Cell viability by trypan blue assay | MDA-MB-231 | 10–100 μM for 16 h | Apoptotic cell death in concentration- and time-dependent manner was observed with cell shrinkage and cytoplasmic membrane blebbing. | [ |
| DAS | Cell viability, cell cycle and apoptosis by PI staining by flow cytometric assay | HeLa | 25–100 µM for 24 h | DNA damage and fragmentation. | [ |
| DATS | Comet assay | PC-3 cells transfected with the plasmid encoding p66ShcS36A or an empty pcDNA3.1 vector | After 24 of transfection, cells were treated with DATS (0–40 µM) | DATS increased p66Shc phosphorylation at serine 36, which was abolished by JNK inhibitor, and DATS-induced ROS formation was abolished in cells expressing p66ShcS36A variant. In cells expressing this variant, DATS-induced Akt dephosphorilation was reduced. The signaling pathway with P66Shc could be indispensable for DATS-induced prostate cancer cell death by modulating the Akt activity and ROS generation. | [ |
| DATS | ROS by flow cytometryProtein levels by ImmunoblottingLabile iron poolDNA damage by comet assay and microscopy | PC-3 | 40 µM for 4 h | DATS-mediated increase in labile iron pool is regulated by JNK1 but not JNK2. Ferritin degradation in PC-3 cells treated with DATS is controlled by JNK1. DATS-induced increase in ROS formation is JNK1-dependent. Iron is not involved in DATS-induced cell death. DATS-induced DNA damage is not ameliorated by iron chelation. | [ |
| DATS | Cell viability by MTT assay | Primary colorectal cancer cells | 10–40 µM for 24 h | Viability inhibition in a concentration-dependent way. | [ |
| DATS | Cell survival by sulforhodamine B assay | PC-3 | 40 µM for 24 h | PNT1A cells are more resistant to cytotoxic effects than PC-3 cells. In these cells, reduction of induced p66Shc | [ |
| Cytotoxicity by Trypan blue exclusion assay and MTT assay | MCF-7 | 10–100 µg/mL, 48 h | IC50(MCF-7) = 21 ± 1.4 µg/mL | [ | |
| S-Allylmercaptocyteine | Cell proliferation by [3H] thymidine incorporation assay | HEL | 0.02, 0.05, 0.1, 0.25 mM 24 h in HEL cells | Significant reduction in [3H] thymidine incorporation | [ |
| Allicin | Cell proliferation by MTT assay | SGG-7901 | Not revealed | Growth inhibition in a concentration-dependent manner | [ |
| DADS | Cell viability by MTT assay | ECA109 | 10–60 µg/mL for 24 h | Cell viability inhibition in a concentration-dependent manner in ECA109. Less toxic in L02 | [ |
| DADS | Cell viability by MTT assay | ECA109 | 10–60 µg/mL for 24–72 h | Cell viability Inhibition in a concentration-dependent manner. | [ |
| PTSO | Ames test | 5–100 µM for the different assays, depending on the viability of the cells (Trypan blue exclusion test) | PTSO was not mutagenic in the Ames test, although it was weak mutagenic in the MLA assay after 24 of treatment (2.5–20.0 µM). The parent compound did not induce MN on mammalian cells, although in presence S9, induced positive results (20 µM). PTSO did not induce DNA breaks or oxidative damage in the comet assays. | [ | |
| DPS, DPDS, and mixtures | Cell viability by PC, NR, MTS | Caco-2 cells | 0–200 µM for 2, 4, 8 h | No cytotoxicity or mutagenicity and no significant adverse effects were reported. ROS scavenger activity was observed for both compounds. | [ |
| Allicin | Cell viability by MTT assay | MGC-803 | 0.5–10 µg/mL for 48 h | Cell viability is affected in a concentration and time-dependent manner. | [ |
| DAS, DADS, DATS | Cytotoxicity assay by cell counting kit-8Protein expression by western blottingCaspase-8 and 9 activityImmunofluorescence analysisLuciferase reporter assayRT-PCR | BC3BCBL1HBL6BC2Ramos | 1–50 µM for 24 h | DAS and DADS slightly decreased viability | [ |
| PTS | Ames test | 0–280 µM for the different assays, depending on the viability of the cells (total protein, NRU, MTS) | Not mutagenic neither in the Ames test nor in MLA. Genotoxic effects were reported in the MN test at the highest concentration assayed (17.25 µM) without S9, and also its metabolites (+S9, from 20 µM). | [ | |
| DATS | Cell viability by MTT assay | AGS | 0–50 µM for 0–24 h | Concentration- and time-dependent decrease of cell viability in AGS cells. No effect on Chang liver cells. | [ |
| DATS | Cell viability by trypan blue exclusion assay | U87MG | 25–50 µM for 30 min | Up-regulated DR5 receptor expression, and enhanced TRAIL-induced apoptosis through the downregulation of anti-apoptotic protein Mcl-1 and the upregulation of DR5 receptors through actions on the ROS-induced-p53 | [ |
| Allicin | Cytotoxicity by MTT assay | U251 | 15–90 µg/mL for 24 h. | Cytotoxic effect in a concentration-dependent manner and nuclear morphology changes in U251 cells. IC50 = 41.97 µg allicin/mL for 24 h. | [ |
| DAS | Cell viability by MTT assay | 3T3L1 | 100 mM ethanol and treated with 50–500 µM DAS for 24 and 48 h. | ↑ viability in ethanol-exposed 3T3L1 cells treated with 200–500 µM for 24 h and 50–500 µM for 48 h. | [ |
| Allicin | MTT assay | CD44+
| CD44+: 4–32 µg allicin/mL or 8–125 µg ATRA/mL or 5 µg/mL of allicin during 4 h followed by 8–125 µg ATRA/mL. Total time of exposure 48 h. | IC50 CD44+: allicin/ATRA (17.53 µg/mL) ˂ allicin (29.19 µg/mL) ˂ ATRA (37.43 µg/mL) | [ |
| DADS | Cell viability by trypan blue assay | HCT116 | 5–100 µM for 24 h. | 0–10 µM caused ˂20% CRC cell deaths. | [ |
| Polymer films of | Cell viability by MTT assayAmes testMN assay | HepG2 GM-07492 | Eluates from HTP-films and W-HTP films containing onion pulp were used at different concentrations | Cytotoxicity: HTP > W-HTP. | [ |
| Triploid onium | Proliferation assay by MTS | Hela, HCT116, and U2OS human cancer cell lines | Serial dilutions of extracts from both | Antiproliferative effects of both species were reported in the three cell lines. They induced apoptosis in HeLa cells. | [ |
| Allicin | Determination of LC50 |
| Not revealed | LC50 = 315 µL/L | [ |
Risk of bias for the methodological quality of studies reporting the toxicological evaluation in vitro of OSCs from Allium spp. 0: not reported; 1: not appropriately or clearly evaluated; 2: appropriately evaluated. M: medium (5–7); L: low (8–10); H: high (0–4).
| Reference | Clear Objective | Well Characterized Product | Reproducibility of the Assay | Comparability | Adequate Statistical Analysis | Total | Risk of Bias | General Risk of Bias |
|---|---|---|---|---|---|---|---|---|
| [ | 2 | 2 | 1 | 2 | 0 | 7 | 3 | M |
| [ | 2 | 2 | 1 | 2 | 0 | 7 | 3 | M |
| [ | 1 | 2 | 1 | 1 | 2 | 7 | 3 | M |
| [ | 2 | 2 | 2 | 1 | 1 | 8 | 2 | L |
| [ | 2 | 1 | 1 | 2 | 2 | 8 | 2 | L |
| [ | 2 | 2 | 1 | 1 | 2 | 8 | 2 | L |
| [ | 2 | 0 | 2 | 2 | 2 | 8 | 2 | L |
| [ | 2 | 2 | 2 | 2 | 2 | 10 | 0 | L |
| [ | 2 | 1 | 2 | 2 | 2 | 9 | 1 | L |
| [ | 2 | 2 | 2 | 1 | 0 | 7 | 3 | M |
| [ | 2 | 2 | 1 | 1 | 2 | 8 | 2 | L |
| [ | 2 | 2 | 2 | 2 | 2 | 10 | 0 | L |
| [ | 1 | 1 | 2 | 2 | 0 | 6 | 4 | M |
| [ | 2 | 2 | 1 | 2 | 0 | 5 | 5 | M |
| [ | 2 | 0 | 2 | 2 | 2 | 8 | 2 | L |
| [ | 2 | 2 | 1 | 2 | 2 | 9 | 1 | L |
| [ | 1 | 2 | 1 | 2 | 2 | 8 | 2 | L |
| [ | 2 | 2 | 2 | 2 | 2 | 10 | 0 | L |
| [ | 2 | 2 | 1 | 2 | 2 | 9 | 1 | L |
| [ | 2 | 1 | 1 | 2 | 0 | 6 | 4 | M |
| [ | 2 | 0 | 2 | 2 | 2 | 8 | 2 | L |
| [ | 2 | 2 | 2 | 2 | 1 | 9 | 1 | L |
| [ | 2 | 2 | 0 | 2 | 2 | 8 | 2 | L |
| [ | 2 | 2 | 1 | 2 | 2 | 9 | 1 | L |
| [ | 2 | 2 | 2 | 2 | 0 | 8 | 2 | L |
| [ | 2 | 0 | 1 | 2 | 2 | 7 | 3 | M |
| [ | 2 | 2 | 1 | 1 | 2 | 8 | 2 | L |
| [ | 1 | 2 | 1 | 1 | 2 | 7 | 3 | L |
| [ | 2 | 2 | 2 | 1 | 2 | 9 | 1 | L |
| [ | 2 | 2 | 2 | 2 | 2 | 10 | 0 | L |
| [ | 2 | 2 | 2 | 2 | 2 | 10 | 0 | L |
| [ | 2 | 2 | 1 | 1 | 2 | 8 | 2 | L |
| [ | 2 | 2 | 1 | 2 | 2 | 9 | 1 | L |
| [ | 2 | 2 | 2 | 2 | 2 | 10 | 0 | L |
| [ | 2 | 2 | 2 | 2 | 0 | 8 | 2 | L |
| [ | 2 | 2 | 2 | 2 | 2 | 10 | 0 | L |
| [ | 2 | 2 | 2 | 1 | 2 | 9 | 1 | L |
| [ | 2 | 1 | 1 | 1 | 2 | 8 | 2 | L |
| [ | 2 | 2 | 2 | 2 | 2 | 10 | 0 | L |
| [ | 2 | 1 | 1 | 2 | 0 | 6 | 4 | M |
| [ | 2 | 0 | 2 | 1 | 2 | 7 | 3 | M |
| [ | 2 | 2 | 2 | 2 | 2 | 10 | 0 | L |
| [ | 2 | 2 | 0 | 0 | 0 | 4 | 6 | H |
Figure 2Graphical model: (A) reported beneficial health effects, (B) in vitro toxicological evaluation and (C) reported results.